- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- B-Cell lymphoma (follicular lymphoma)
- Bladder cancer (UroVysion FISH analysis)
- Breast cancer (HER-2/neu FISH analysis)
- Chronic lymphocytic leukemia B cell type (B-CLL)
- Chronic myeloic leukemia(CML)
- del (4)(q12) (FIP1l1-PDGFRA)
- del(11)(q22.3) (ATM)
- del(13)(q14) (DLEU1)
- del(17)(p13) (P53)
- del(20)(q11.2-q12) (MLRG)
- del(5)(q31) (EGR1)
- Deletion Diagnostics
- Imatinib (tyrosine kinase inhibitor) resistance
- JAK2-V617F mutation
- Molecular Pathology
- Monosomy 7
- Multiple myeloma (plasma cell myeloma / Kahler's disease)
- Myelodysplastic syndrome (MDS)
- Myeloproliferative syndrome (MPS)
- Polycythemia rubra vera-1 (PRV-1) - overexpression
- Polycythemia vera
- t(11;14)(q13;q32) (IGH/CCND1)
- t(11;18)(q21;q21) (MALT1)
- t(11;V)(q23;V) (MLL)
- t(14;18)(q32;q21) (IGH/BCL2)
- t(15;17)(q22;q12.1) (PML/RARa)
- t(16;16)((p13;q22), inv(16) (CBFB)
- t(8;21)(q22;q22) (AML1/ETO)
- t(9;22)(q34;q11.2) (BCR/ABL)
- Translocation Diagnostics
- Tyrosine kinase inhibitor (imatinib) resistance
|
|
|
|
Accredited according to:
DIN EN ISO /IEC 17025,
DIN EN ISO 15189,
European Fed. of Immunogenetics (EFI)
|
|
